# US 2020/0368210 A1 · Dual inhibitors of tim-3 and pd-1 pathways

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368210 A1
- Document ID: US20200368210A1
- Status: Published application
- Kind: A1
- Application number: 16/761,162
- Filed: 2018-10-31
- Published: 2020-11-26
- Earliest claimed: 2017-11-03
- Assignees: Aurigene Discovery Technologies Limited
- Applicants: Aurigene Discovery Technologies Limited
- Inventors: Pottayil Govindan N. Sasikumar; Muralidhara Ramachandra; Seetharamaiah Sethy S. Naremaddepalli; Nagaraj Gowda
- Web page: https://patentgrep.com/patent/US20200368210A1

## CPC

- A61K 31/4245: Oxadiazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

## Claims

### Claim 1

A method of modulating an immune response mediated by T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) activity in a subject, comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
Z represents —OH or —NH-G;
G represents hydrogen or (C1-C6)alkyl;
Y represents hydrogen or a group represented by the following structural formula
Ra represents (C1-C6)alkyl substituted with —OH, —NRxRy, —SRx, carboxylic acid, guanidino, or aryl, wherein the aryl group is optionally further substituted with hydroxyl; or Ra and G taken together with the atom to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S;
Ra′ represents hydrogen; or Ra and Ra′ taken together with the atom to which they are attached form a 5- to 6-membered ring, optionally containing 1 to 3 heteroatoms selected from O, N or S;
Rb represents (C1-C6)alkyl, optionally substituted with —C(O)NRxRy, —NRxRy, or carboxylic acid;
Rc represents hydrogen; or Rb and Rc taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S, wherein the 5- to 6-membered ring is optionally further substituted with hydroxyl;
Rd represents (C1-C6)alkyl, optionally substituted with —ORx, carboxylic acid, or aryl-OH;
Re represents hydrogen; or Rd and Re taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S; and
Rx and Ry independently represent hydrogen, (C1-C6)alkyl or (C2-C6)acyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein Z represents —NH-G.

### Claim 3 (depends on 1)

The method of claim 1, wherein G represents hydrogen or methyl.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein Z represents —OH.

### Claim 6 (depends on 1)

The method of claim 1, wherein Ra represents (C1-C4)alkyl, wherein (C1-C4)alkyl is substituted with —OH, —NRxRy, —NH—C(═NH)—NH2, —SRx, carboxylic acid, or aryl, wherein the aryl group is optionally further substituted with hydroxyl.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein Ra represents —CH2OH, —CH(CH3)OH, —(CH2)4—NH2, —(CH2)2—SCH3, —(CH2)2C(O)OH, —(CH2)3—NH—C(═NH)—NH2, —CH2-(phenyl), or —CH2-(p-OH(phenyl)).

### Claim at position 10

10-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein Ra and G taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein Ra and Ra′ taken together with the atoms to which they are attached form a 5- to 6-membered ring, optionally containing 1 to 3 heteroatoms selected from O, N or S.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein Rb represents (C1-C4)alkyl, wherein (C1-C4)alkyl is optionally substituted with —C(O)NRxRy, —NRxRy, or carboxylic acid.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein Rb represents sec-butyl, —CH2C(O)NH2, —(CH2)4—NH2, —(CH2)4—NH(C(O)CH3), —CH2C(O)OH, or —(CH2)2C(O)OH.

### Claim at position 19

21-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein Rb and Rc taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S, wherein the 5- to 6-membered ring is optionally further substituted with hydroxyl.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein Y represents a group represented by the following structural formula

### Claim 27 (depends on 1)

The method of claim 1, wherein Rd represents (C1-C4)alkyl, optionally substituted with —OH, —OCH3, —C(O)OH, or p-OH(phenyl); and Re represents hydrogen.

### Claim at position 24

28-30. (canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein Rd and Re taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein:
Z represents —OH, or —NH-G;
G represents hydrogen or (C1-C6)alkyl;
Y represents a group represented by the following structural formula
Ra represents (C1-C6)alkyl substituted with —OH, —NH2, carboxylic acid, guanidino, or phenyl;
Ra′ represents hydrogen; or Ra and Ra′ taken together with the atom to which they are attached form a 5- to 6-membered ring, optionally containing 1 to 3 heteroatoms selected from O, N or S;
Rb represents (C1-C6)alkyl, optionally substituted with —C(O)NRxRy or carboxylic acid;
Rc represents hydrogen; or Rb and Rc taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S;
Rd represents (C1-C6)alkyl, optionally substituted with —ORx;
Re represents hydrogen; or Rd and Re taken together with the atoms to which they are attached form a 5- to 6-membered ring containing 1 to 3 heteroatoms selected from O, N or S; and
Rx and Ry independently represent hydrogen, (C1-C6)alkyl or (C2-C6)acyl.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein:
Z represents —OH, or —NH-G;
G represents hydrogen or methyl;
Y represents a group represented by the following structural formula
Ra represents —CH2OH, —CH(CH3)OH, —(CH2)4—NH2, —(CH2)2C(O)OH, —(CH2)3—NH—C(═NH)—NH2, or —CH2-(phenyl);
Ra′ represents hydrogen;
Rb represents —CH2C(O)NH2, —CH2C(O)OH, or —(CH2)2C(O)OH;
Rc represents hydrogen; or Rb and Rc taken together with the atoms to which they are attached to form a pyrrolidine ring;
Rd represents sec-butyl, —CH2OH, or —CH(CH3)OH; and
Re represents hydrogen.

### Claim at position 31

37-41. (canceled)

### Claim 42 (depends on 1)

The method of claim 1, wherein the compound is selected from:
Compound
No.
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
or pharmaceutically acceptable salt thereof.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway.

### Claim 46 (depends on 1)

The method of claim 1, wherein the immune response is further mediated by an agent that modulates TIM 3.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

The method of claim 1, wherein the subject is suffering from a disease or disorder selected from cancer, an immune disorder, an immunodeficiency disorder, an inflammatory disorder, an infectious disease, and transplant rejection; and the method treats the disease or disorder.

### Claim 49 (depends on 48)

The method of claim 48, wherein the disease or disorder is cancer.

### Claim 50 (depends on 49)

The method of claim 49, wherein the cancer is mediated by TIM-3 or an agent that modulates TIM-3.

### Claim at position 41

51-53. (canceled)

### Claim 54 (depends on 49)

The method of claim 49, wherein the cancer is selected from breast cancer, colon cancer, liver cancer, ovarian cancer, prostate cancer, renal cancer, and uterine cancer.

### Claim 55 (depends on 49)

The method of claim 49, wherein the cancer is a hematopoietic cancer.

### Claim 56 (depends on 55)

The method of claim 55, wherein the hematopoietic cancer is selected from a lymphoma, B cell lymophoma, T cell lymphoma, Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, a leukemia, a myeloma, acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphoblastic leukemia (CLL), chronic myelomonocytic leukemia (CMML), multiple myeloma, myelodysplastic syndrome (MDS), and plasmacytoma.

### Claim 57 (depends on 49)

The method of claim 49, wherein the cancer is selected from ovarian cancer, colon cancer, breast cancer, lung cancer, a myeloma, a neuroblastic-derived CNS tumor, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, a B-cell derived lymphoma, a T-cell derived lymphoma, and a mast cell derived tumor.

### Claim 58 (depends on 49)

The method of claim 49, wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, connective tissue cancer, eye cancer, throat cancer, oral cavity cancer, biliary tract cancer, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, endometrial cancer, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, thyroid cancer, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), myeloproliferative disorder/neoplasm (MPDS), myelodysplasia syndrome, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, solid tumors of childhood, a B-cell derived lymophoma, T-cell dervied lymphoma, Hodgkin's lymphoma, indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, follicular lymphoma, mesothelioma, thymic carcinoma, myeloma, multiple myeloma, giant cell myeloma, heavy-chain myeloma, light chain or Bence-Jones myeloma, a mast cell derived tumor, leiomyoma, leiomyosarcoma, glioma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neuroblastic-derived CNS tumors, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, Meigs' syndrome, Merkel cell carcinoma, and environmentally induced cancers.

### Claim 59 (depends on 48)

The method of claim 48, wherein the disease or disorder is an infectious disease.

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 48)

The method of claim 48, wherein the disease or disorder is an immune disorder, immunodeficiency disorder, or an inflammatory disease.

### Claim at position 51

63-85. (canceled)
